Aclaris Therapeutics (ACRS) Long-Term Investments (2014 - 2026)

Aclaris Therapeutics' Long-Term Investments history runs 10 years deep, the most recent figure standing at $85.4 million for Q1 2026.

• On a quarterly basis, Long-Term Investments changed 0.19% year-over-year to $85.4 million in Q1 2026; TTM through Mar 2026 was $85.4 million, a 0.19% change from a year earlier, with the FY2025 full-year figure at $60.6 million, down 32.88% from the prior year.
• Long-Term Investments improved to $85.4 million in Q1 2026 per ACRS's latest filing, from $60.6 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $91.0 million in Q2 2023 and bottomed at $7.2 million in Q2 2022.
• The 5-year median for Long-Term Investments is $61.7 million (2023), against an average of $56.6 million.
• Across the five-year window, Long-Term Investments tumbled 79.07% in 2022 and soared 1160.1% in 2023, its largest moves.
• Year by year, Long-Term Investments stood at $12.2 million in 2022, then soared by 412.75% to $62.8 million in 2023, then soared by 43.86% to $90.3 million in 2024, then plunged by 32.88% to $60.6 million in 2025, then soared by 40.85% to $85.4 million in 2026.
• Per Business Quant, the three latest ACRS Long-Term Investments figures stand at $85.4 million (Q1 2026), $60.6 million (Q4 2025), and $71.3 million (Q3 2025).